Skip to content

Advertisement

Arthritis Research & Therapy

Research article
Open Access

A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

  • Krishanu Sengupta1,
  • Krishnaraju V Alluri2,
  • Andey Rama Satish3,
  • Simanchala Mishra4,
  • Trimurtulu Golakoti5,
  • Kadainti VS Sarma6,
  • Dipak Dey7 and
  • Siba P Raychaudhuri8Email author
Arthritis Research & Therapy200810:R85

https://doi.org/10.1186/ar2461

©  Sengupta et al.; licensee BioMed Central Ltd. 2008

Received: 24 November 2007

Accepted: 30 July 2008

Published: 30 July 2008

Abstract

Introduction

5-Loxin® is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-Loxin® in the treatment of osteoarthritis (OA) of the knee.

Methods

Seventy-five OA patients were included in the study. The patients received either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin® daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients. Measurement of a battery of biochemical parameters in serum and haematological parameters, and urine analysis were performed to evaluate the safety of 5-Loxin® in OA patients.

Results

Seventy patients completed the study. At the end of the study, both doses of 5-Loxin® conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin® as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3. In comparison with placebo, the safety parameters were almost unchanged in the treatment groups.

Conclusion

5-Loxin® reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin® may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.

Trail Registration

(Clinical trial registration number: ISRCTN05212803.)

Keywords

Synovial FluidEtoricoxibWOMAC ScoreSynovial Fluid SampleClinical Trial Registration Number

Introduction

Osteoarthritis (OA) is the commonest form of inflammatory joint disease, characterized by articular cartilage degradation with an accompanying peri-articular bone response [1, 2]. OA affects nearly 21 million people in the USA, accounting for 25% of visits to primary care physicians. It is estimated that 80% of the population will have radiographic evidence of OA by age 65 years, although only 60% of those will be symptomatic [3]. Clinical manifestations of OA of the knee include pain in and around the joint, stiffness of the joint after rest, crepitating on motion and limited joint motion, among others [4]. Current recommendations for managing OA focus on relieving pain and stiffness and improving physical function as important goals of therapy [5, 6]. Currently available medication regimens for most cases include nonopioid analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclo-oxygenase II inhibitors. These pharmaceutical agents can reduce both pain and inflammation quite effectively, but long-term use of NSAIDs has been found to be associated with enhanced risk for gastrointestinal bleeding, hypertension, congestive heart failure and renal insufficiency, among other adverse effects [7–9]. Because of the high incidence of adverse events associated with both nonselective and cyclo-oxygenase II selective NSAID therapy, effective and safer alternative treatments for OA are urgently needed.

In recent years, the gum resin extracted from the ancient herb Boswellia serrata has gained much attention as a potent anti-inflammatory, anti-arthritic and analgesic agent [10, 11]. 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) is the most active component of Boswellia extract and has been demonstrated to be a potent inhibitor of 5-lipoxygenase (5-LOX), which is a key enzyme in the biosynthesis of leukotrienes from arachidonic acid in the cellular inflammatory cascade [12, 13].

5-Loxin® is a novel B. serrata extract enriched to 30% AKBA (US Patent publication no.: 2004/0073060A1). In the carrageenan-induced inflammation model, 5-Loxin® treatment yielded significant improvement in paw inflammation in albino Wister rats [14]. Cell based in vitro studies and in vivo experiments conducted in Sprague-Dawley rats suggest that 5-Loxin® can inhibit proinflammatory cytokines such as tumour necrosis factor-α, interleukin-1β (unpublished data, Sengupta K, Alluri KV, and Golakoti T). Furthermore, Affimatrix gene chip analysis demonstrates 5-Loxin® can potentially inhibit the tumour necrosis factor-α induced gene expression of matrix metalloproteinases (MMPs), adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and mediators of apoptosis in human microvascular endothelial cells [14]. Importantly, extensive acute and dose-dependent subchronic safety experiments on rats demonstrate that 5-Loxin® does not exhibit toxic manifestations, even at a dose 2,000 to 3,000 times higher than the human equivalence dose [15]. In addition, 5-Loxin® does not exhibit genotoxicity in the standard AMES bacterial reverse mutation assay (INTOX, 375, Urawade, Pirangut-Urawade Road, Tal. Mulshi, Pune – 412108, India; study no. 4477/05).

Although a significant number of clinical study reports support the anti-inflammatory and anti-arthritic properties of Boswellia extract [16–19], to the best of our knowledge no reports on the efficacy of AKBA-enriched 5-Loxin® in OA in humans have been published. Therefore, in the present double-blind and placebo-controlled clinical study, we sought to evaluate the efficacy and safety of 5-Loxin® in treatment of OA of the knee. We assessed the effectiveness of 100 mg/day and 250 mg/day 5-Loxin® on pain, joint stiffness and mobility in OA patients. We also explored the effect of 5-Loxin® on the cartilage degrading enzyme MMP-3 in OA patients treated with 5-Loxin®.

Materials and methods

Recruitment of patients

This trial was performed at Alluri Sitarama Raju Academy of Medical Sciences (ASRAM), Eluru, Andhra Pradesh, India from July 2006 to October 2006 (clinical trial registration number: ISRCTN05212803). The study protocol was evaluated and approved by the ASRAM Institutional Review Board. An overview of the clinical study is provided in Figure 1. Briefly, 236 patients out of 823 attending the orthopaedic Outpatients Department of the ASRAM Hospital were selected, based on the signs, symptoms and radiological changes consistent with OA in the first phase of the screening procedure. A total of 75 patients suffering for more than 3 months with medial tibiofemoral OA were selected using inclusion/exclusion criteria summarized in Table 1. All patients signed the Institutional Review Board approved consent form. Patients were otherwise healthy, were aged 40 years or older, and had a diagnosis of OA, fulfilling the American College of Rheumatology classification criteria [4]. After recruitment, the patients were randomly distributed into three groups; demographic data and baseline characteristics are summarized in Table 2.
Table 1

Inclusion/exclusion criteria

Criteria

Details

Inclusion

Patients must understand risks and benefits of the protocol and be able to give informed consent

 

Male and female patients aged 40 to 80 years

 

Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result.

 

Unilateral or bilateral osteoarthritis of the knee for more than 3 months

 

Visual analogue scale score during the most painful knee movement between 40 and 70 mm after 7 days of withdrawal of usual medication

 

Lequesne's Functional Index score greater than 7 points after 7 days of withdrawal of usual medication

 

Ability to walk

 

Availability for the duration of the entire study period

Exclusion

History of underlying inflammatory arthropathy or severe rheumatoid arthritis

 

Hyperuricaemia (>440 μmol/l) and/or past history of gout

 

Recent injury in the area affected by osteoarthritis of the knee (past 4 months) and expectation of surgery in the next 4 months

 

Intra-articular corticosteroid injections within the preceding 3 months

 

Hypersensitivity to nonsteroidal anti-inflammatory drugs, abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal haemorrhage, congestive heart failure, hypertension, hyperkalaemia

 

Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders

 

High alcohol intake (>2 standard drinks per day)

 

Pregnant, breastfeeding, or planning to become pregnant during the study

 

Use of concomitant prohibited medication other than ibuprofen

 

Obesity (body mass index > 30 kg/m2)

Table 2

Demographic data and baseline characteristics of the patients

Characteristics

Placebo (n = 23)

100 mg/day 5-Loxin® (n = 24)

250 mg/day 5-Loxin® (n = 23)

Sex (male/female; n)

5/18

7/17

8/15

Age (years)

52.43 ± 9.65

52.37 ± 8.37

53.22 ± 8.73

Body weight (kg)

61.48 ± 10.69

61.08 ± 10.67

54.84 ± 10.19

Body mass index (kg/m2)

26.05 ± 4.29

25.91 ± 4.94

22.64 ± 4.07

Visual analog score (mm)

56.88 ± 12.04

57.05 ± 8.71

55.62 ± 9.26

Lequesne's Functional Index

12.76 ± 2.6

12.1 ± 2.76

12.04 ± 3.03

WOMAC score

   

   Pain subscale

38.04 ± 9.7

48.08 ± 14.05

37.17 ± 13.8

   Stiffness subscale

33.15 ± 13.3

31.8 ± 17.6

27.7 ± 16.8

   Function subscale

41.3 ± 9.6

41.5 ± 11.1

38.6 ± 11.1

Values are expressed as mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Figure 1
Figure 1

Flow chart of the patients who participated in the clinical trial. Evaluations of physical activity and pain scores, serum biochemistry, haematology, urine biochemistry and proinflammatory cytokines were done at baseline (day 0) and on days 7, 30, 60 and 90 during follow up. Assessments of matrix metalloproteinase-3 were done on days 0 and 90 only.

Before study enrollment, patients were required to be taking an NSAID at prescription strength for at least 30 days or acetaminophen 1,200 to 4,000 mg/day on a regular basis (at least 25 of the preceding 30 days) with a history of therapeutic benefit. Eligibility required patients to meet specific flare criteria upon medication washout. At screening, patients had to demonstrate a visual analog scale (VAS) score between 40 and 70 mm during the most painful knee movement, and Lequesne's Functional Index (LFI) score greater than 7 points after 7-day withdrawal of usual medication.

Study design

A total of 75 selected patients with symptoms of moderate to mild OA were recruited into the study. Each patient was randomly assigned to a treatment group using a randomization table generated using validated computer software (RANCODE; IDV, Gauting, Germany). Treatment allocation depended only on the time sequence in which patients entered the study, thus minimizing selection bias. The clinical trial pharmacist and statistician ensured that treatment codes remained confidential. The patients were distributed into three groups: placebo (n = 25); 30% AKBA enriched B. serrata extract (5-Loxin®) low-dose group (100 mg/day), in which patients received 50 mg encapsulated 5-Loxin® twice daily (n = 25); and 5-Loxin® high-dose group (250 mg/day), in which patients received 125 mg encapsulated 5-Loxin® twice daily (n = 25). Patients in the placebo group received two capsules of similar color, taste and appearance but filled only with rice bran.

Each patient completed a questionnaire, providing details regarding demographics, medical history and nutritional status, at the baseline evaluation and during the follow-up evaluations on days 7, 30, 60 and 90. At the baseline evaluation, and at each visit during the 90-day follow up period, all patients were assessed for pain scores and physical ability. Various parameters of serum biochemistry, haematology and urine analysis were carried out on each evaluation day. Serum samples were collected at all evaluation days for proinflammatory modulators. Knee joint synovial fluid was aseptically collected at baseline and at day 90 for evaluation of MMP-3 concentration. Safety was monitored by clinical and laboratory assessments conducted at study visits and patient-reported adverse experiences.

Functional disability and pain score evaluation

The investigators assessed the functional disability reported by the patients at baseline and on each follow-up visit (days 7, 30, 60 and 90). Questionnaire-based assessment of pain, stiffness and physical function were done using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) index [20], LFI [21] and VAS [22]. The WOMAC index produces scores for three subscales: pain, stiffness and physical function. The pain, stiffness and function subscales of the WOMAC were converted to a 0 to 100 normalized units (NU) scale [23]. The pain subscale was the average of the first five questions of WOMAC and measured using the NU scale from 0 mm ('no pain') to 100 mm ('extreme pain') for each question. The stiffness subscale was the average of questions 6 and 7, measured using the NU scale from 0 mm ('no stiffness') to 100 mm ('extreme stiffness') for each question. The physical function subscale was the average of questions 8 through 24 of the WOMAC and measured by NU scale from 0 mm ('no difficulty') to 100 mm ('extreme difficulty') for each question. Analyses of these end-points were based upon the time-weighted average change from baseline over 90 days.

Haematological and biochemical evaluations

For assessment of safety of 5-Loxin®, several parameters were evaluated in serum, urine and whole blood of all patients at each visit of the study duration (Table 3). Serum biochemical parameters and haematological parameters were measured using the automated analyzer HumaStar 300 (Human, Wiesbaden, Germany) and the haematological counter Humacount (Human), respectively. The urine analysis was carried out by microscopy and by using UroColor™10 Dip Sticks (Standard Diagnostics, Kyonggi-do, Korea).
Table 3

Parameters tested in serum biochemistry, haematology and urine analysis

Analysis

Details

Serum biochemistry

Albumin

 

Alkaline phosphatase

 

Total bilirubin

 

Cholesterol

 

Creatinine

 

Creatine kinase-N-acetyl cysteine

 

Glucose

 

High-density lipoprotein

 

Low-density lipoprotein

 

Potassium

 

Serum glutamic oxaloacetate transaminase

 

Serum glutamate pyruvate transaminase

 

Triglycerides

 

Urea

Haematology

Total count and differential count

 

Erythrocyte sedimentation rate

 

Haemoglobin

 

Platelet count

 

Mean corpuscular volume

 

Mean corpuscular hemoglobin

Urine analysis

Specific gravity

 

pH

 

Albumin

 

Bile salt

 

Bile pigment

 

Glucose

 

Red blood cell count

 

Ketone bodies

Assessment of matrix metalloproteinase-3 in synovial fluids

MMP-3 (R&D Systems, Minneapolis, USA) were quantitatively measured by ultrasensitive ELISA method. Assay procedures adhered to the protocol supplied by the manufacturers. Briefly, synovial fluid samples were incubated on capture antibody coated 96-well microplates. Specifically bound antigen was detected by appropriate biotinylated detection antibody and was probed with horseradish peroxidase enzyme. The specific immune reaction was detected by substrate solution and the colour development was read with the help of micro-plate reader (Bio-Rad, Hercules, CA, USA). A standard curve was generated by plotting the optical density at respective known concentration of MMP3. The sensitivity of MMP-3 detection ELISA kit is 9 pg/ml.

Rescue medication

Patients were prescribed ibuprophen 400 mg tablets (maximum 400 mg thrice daily; total 1,200 mg) as rescue analgesia on days 7, 30 and 60, based on pain intensity reported to the study physician by the patient. However, the patients were instructed not to take medicine at least 3 days before each evaluation. No other OA interventions were allowed during the study period.

Statistical analysis

We performed detailed statistical analyses using SAS software to evaluate the efficacy of two doses of 5-Loxin® in comparison with the placebo group in terms of improvement in pain and physical ability scores, and to assess biomolecular markers at baseline and days 7, 30, 60 and 90 of treatment. Pair-wise changes were examined by carrying out a least significant difference test for all possible pairs. The significance of the effects of the treatment groups was compared by using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. Results with P < 0.05 are considered statistically significant.

This is a three-arm (two doses of 5-Loxin® and placebo), randomized, double-blind, placebo-controlled, single-centre trial conducted over 90 days. The trial's primary objective was to determine the effects of 5-Loxin® on pain, physical function and joint stiffness. For power calculations, the estimates for variability and assumed mean changes for each treatment group were based on results from previous placebo-controlled studies of celecoxib, etoricoxib and rofecoxib conducted in patients with OA [24–27]. We believe that an intervention that gives an average improvement of mean change + 1 standard deviation, rather than mean change only, will provide results of greater significance [28]. Our trial is designed to have more than 80% power to detect a situation in which either active drug dosage yields an improvement to at least mean change + 0.9 standard deviation, under a conservative assumption, and we tested differences between groups in mean improvement using ANOVA (α = 0.05, two-sided). With 25 patients per group, we would have a 93% chance of observing at least one example of any side effect occurring in 10% or more of the patient population at a specific dosage.

Results

Baseline characteristics

Descriptive statistics comparing demographic variables, baseline disease characteristics and baseline outcome measures (that is, WOMAC pain, function and stiffness subscores) are provided in Table 2. Overall, the treatment groups receiving 5-Loxin® low dose (100 mg/day, n = 25), 5-Loxin® high dose (250 mg/day, n = 25) and placebo (n = 25), were similar with respect to sex, age, Body Mass Index and pain severity (Table 2). The patients were randomly distributed into three groups. Although there are some differences in baseline characteristics of gender, body mass index and WOMAC scores, those are statistically not significant.

Clinical efficacy

We compared the scores between the treatment groups obtained at day 90. Both doses of 5-Loxin® conferred clinically and statistically significant improvements in pain scores and physical ability scores in OA patients between baseline and day 90 (Table 4).
Table 4

Student's t-test (paired) analyses for comparison of the scores obtained from the low-dose and high-dose 5-Loxin® groups at day 90

 

n

Baseline

Day 90

95% CI (versus placebo)

P

  

Mean

SD

Mean

SD

  

Visual analogue scale score

   Placebo

23

56.88

12.04

41.76

15.98

 

<0.05

   100 mg 5-Loxin®

24

57.05

8.71

21.37

7.13

-27.67, -13.11

<0.0001

   250 mg 5-Loxin®

23

55.62

9.26

14.22

6.8

-34.94, -20.19

<0.0001

Lequesne's Functional Index

   Placebo

23

12.76

2.6

10.19

3.24

 

0.031

   100 mg 5-Loxin®

24

12.1

2.76

7.78

4.61

-4.74, -0.07

<0.0001

   250 mg 5-Loxin®

23

12.04

3.03

7

3.5

-5.19, -1.18

<0.0001

WOMAC pain subscale

   Placebo

23

38.04

2.03

31.74

2.58

 

0.1212

   100 mg 5-Loxin®

24

42.08

2.93

19.17

3.55

-21.33, to -3.83

<0.0001

   250 mg 5-Loxin®

23

37.17

2.88

15.22

2.50

-23.78 to -9.28

<0.0001

WOMAC stiffness subscale

   Placebo

23

33.15

2.73

24.45

2.37

 

0.2983

   100 mg 5-Loxin®

24

31.77

3.61

14.06

3.71

-38.87, -6.85

<0.0001

   250 mg 5-Loxin®

23

27.72

3.44

9.24

2.07

-43.35, -17.45

<0.0001

WOMAC function subscale

   Placebo

23

41.30

2.02

34.07

1.09

 

0.1048

   100 mg 5-Loxin®

24

41.48

2.31

24.32

4.28

-18.64, -0.82

<0.0001

   250 mg 5-Loxin®

23

38.56

2.32

17.267

1.98

-21.39, -12.23

<0.0001

MMP-3 (ng/ml)

   Placebo

15

902.1

275.6

928.5

216.02

 

0.4886

   100 mg 5-Loxin®

16

893.6

270.1

637.2

224.5

 

<0.0001

   250 mg 5-Loxin®

14

926.9

270.5

497.5

167.5

 

<0.0001

CI, confidecne interval; MMP, matrix metalloproteinase; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Tukey's multiple comparison test revealed statistically significant improvements by 48.83% (P < 0.001), 23.79% (P < 0.036) and 39.61% (P = 0.009) in VAS, LFI and WOMAC pain scores, respectively, in the low-dose (100 mg 5-Loxin®) group versus the placebo group (Table 4). Improvements by 42.5% (P = 0.120) and 28.62% (P = 0.100) score in WOMAC stiffness and WOMAC functional ability, respectively were also achieved in the low-dose group (Table 4).

In comparison with the placebo group, the high-dose (250 mg 5-Loxin®) group also exhibited statistically significant improvements in all parameters (Table 4). The high-dose group showed improvements by 65.94% (P < 0.001), 31.34% (P < 0.017), 52.05% (P < 0.001), 62.22% (P = 0.014) and 49.34% (P = 0.002) in VAS, LFI, WOMAC pain, WOMAC stiffness and WOMAC functional ability scores, respectively.

Student's t-test analyses revealed that MMP-3 concentration (P < 0.0001) in synovial fluids and VAS pain scores (P = 0.001) were significantly lower in the high-dose group than in the low-dose group. It is worth noting that both low-dose and high-dose treatment groups exhibited improvement in pain scores and physical ability scores as early as 7 days after the start of treatment, and these indices continued to improve throughout the 90 days of treatment (Figure 2). After 7 days, the low-dose and high-dose treatment groups exhibited 10.09% (P = 0.05) and 12.18% (P = 0.02) reductions in VAS, respectively, compared with the placebo group. In addition, WOMAC physical ability also improved by 14.38% (P < 0.01) after 7 days of treatment with high-dose 5-Loxin® (Figure 2).
Figure 2
Figure 2

Function, pain and stiffness scores. Presented are the mean scores for (a) visual analog scale, (b) Lequesne's Functional Index, (c) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)-pain, (d) WOMAC-stiffness, and (e) WOMAC-functional ability in the low-dose (100 mg/day 5-Loxin®) and high-dose (250 mg/day 5-Loxin®) groups and placebo group at different time points, as indicated. Each bar represents mean concentration ± standard deviation. In comparison with placebo, the change in scores in the treatment groups was tested for significance using Tukey's multiple comparison test; asterisk indicates statistical significance.

Assessment of MMP-3 concentration

OA is a degenerative joint disorder; in molecular pathogenesis of OA, proteolytic enzymes such as MMPs are highly elevated in body fluids such as serum and synovial fluids, which cause potential damage in cartilage tissues [29]. Therefore, in order to determine whether 5-Loxin® treatment can normalize the MMP level, we evaluated the concentration of MMP-3 in synovial fluids collected from the patients. Figure 3 illustrates changes in MMP-3 concentration in synovial fluid samples collected from patients of all groups included in the study. Pair-wise comparisons indicated that at the end of the study both treatment groups exhibited highly significant reductions in MMP-3 in synovial fluid. Compared with the placebo group, the low-dose (100 mg) and high-dose (250 mg) 5-Loxin® groups showed 31.37% (P = 0.002) and 46.4% (P < 0.001) reductions in MMP-3 concentration, respectively. Regular t-tests revealed that high-dose 5-Loxin® treatment significantly reduced (P < 0.0001) synovial MMP-3 concentration when compared with the low-dose group (Table 4). Compared with baseline, the Wilcoxon sign-rank-sum test revealed that the low-dose and high-dose groups conferred 28.69% (P = 0.0013) and 46.33% (P < 0.0001) reductions in synovial fluid MMP-3 concentration at day 90. The MMP-3 level in the placebo group remained virtually unchanged at day 90 compared with baseline.
Figure 3
Figure 3

Reduction of Synovial MMP-3 levels. Presented are the matrix metalloproteinase (MMP)-3 levels in synovial fluid collected from 5-Loxin® treated and placebo patients with osteoarthritis. At day 90 there was no significant change in MMP-3 concentration in the placebo group compared with baseline. In comparison with the placebo group, at the end of the study the groups receiving100 mg/day and 250 mg/day 5-Loxin® showed 31.37% (P = 0.002) and 46.4% (P < 0.001) reductions in MMP-3 concentration, respectively. Change in MMP-3 concentration between the active treatment groups was not significant (P = 0.213). Each bar represents mean concentration of MMP-3 (ng/ml synovial fluid) ± standard deviation.

Biochemical evaluations

As a part of the safety evaluation, laboratory tests were performed to evaluate different biochemical parameters in serum and urine, and haematological parameters. The tested parameters in serum biochemistry, and haematological and urine analysis are summarized in Table 3. The significance of the differences between baseline and 90 days was tested by using repeated measures ANOVA. The F ratio is considered significant if P < 0.05. Although minor changes were observed in some of the parameters, they remained within the normal laboratory range. Statistical analyses of these parameters did not identify any statstically significant changes. Similarly, haematological and urinary parameters also exhibited no significant changes in the active treatment groups compared with placebo (data not shown). These findings further demonstrate the safety of 5-Loxin® in humans.

Adverse events

During the course of the 90-day study period, some minor adverse events were noted: diarrhoea, nausea, abdominal pain, mild fever (up to 37.5°C [99.5°F]) and general weakness. The patients who reported these minor events were distributed evenly throughout the placebo and active treatment groups. The numbers of minor adverse events reported by the patients during the study are summarized in Table 5.
Table 5

Incidence of adverse events

Adverse events

Placebo (n = 23)

100 mg/day 5-Loxin® (n = 24)

250 mg/day 5-Loxin® (n = 23)

Diarrhoea

3

2

2

Nausea

1

3

2

Vomiting

1

1

1

Abdominal pain

4

2

2

Pedal edema

0

1

0

Itching

2

1

4

General weakness

2

4

2

Constipation

0

0

1

Mild fever (up to 37.5°C)

1

2

2

Stomach burn

4

0

3

Allergya

3

0

1

Headache

0

0

1

Miscellaneousb

9

2

6

Sum of events

30

18

27

aAllergy includes redness of skin and sinus allergy. bMiscellaneous group includes body pain, loss of hair, chest pain and eye infection.

Dropouts

Five patients (one from the low-dose [100 mg 5-Loxin®] group, and two each from placebo and high-dose [250 mg 5-Loxin®] group) were excluded from the study because they were suffering from a nonfatal viral infection during the course of study.

Discussion

To the best of our knowledge, this is the first clinical study to evaluate the efficacy of 5-Loxin® in OA. This study also provides important information regarding the possible molecular mechanisms of action of an anti-inflammatory compound of herbal origin in the treatment of OA. We demonstrated that 5-Loxin® has potential efficacy in terms of reducing pain and improving the physical ability of OA patients. A novel aspect of the present study is its evaluation of the effect of 5-Loxin® treatment on the cartilage degrading enzyme MMP-3 in synovial fluid from OA patients. In this 90-day clinical study, we also assessed the safety of 5-Loxin® in OA patients.

Pain, stiffness of joints, reduced joint movement and physical disability are the major clinical manifestations of OA [1, 30]. Our study demonstrates that 5-Loxin® potentially improves pain, joint stiffness and physical function in OA patients (Figure 2). The statistical analyses revealed that the improvements in physical parameters and reductions in synovial MMP-3 levels were significantly decreased in the treatment groups as compared with the placebo group (Figures 2 and 3). In addition, in order to check improvements in the treatment groups, we compared the data for all parameters between the baseline and day 90. Paired t-test revealed that both treatment groups had highly statistically significant improvements in all parameters. Comparing the high-dose versus the low-dose groups at day 90, significant differences were observed only for VAS for pain and synovial fluid MMP3 concentration (Table 4). This finding suggests that the higher dose of 5-Loxin® has better therapeutic efficacy against OA. We observed that, in comparison with baseline, there were downward trends in VAS score, LFI and WOMAC scores in the placebo group. We believe that this might be partly attributable to the placebo effect [31, 32] manifesting while patients completed the questionnaires, and partly due to the consumption of ibuprophen as rescue medication by more patients in the placebo group during the study. Interestingly, at the end of the study we found that the total number of participants requesting rescue medication was 16.7% and 72.2% higher in the placebo group than in the groups receiving 100 mg and 250 mg 5-Loxin®, respectively.

An important observation in the present study is that 250 mg/day 5-Loxin® had a significant effect in lowering VAS score by 12.18% (P = 0.02) and WOMAC function score by 14.38% (P < 0.01) in OA patients as early as 7 days after the start of treatment. These findings therefore indicate that 5-Loxin® confers prompt and significant pain relief and improvement in physical ability in OA patients. Existing information reveals that glucosamine usually takes 6 weeks to achieve significant beneficial effect in terms of pain relief in OA [33]. In addition, a randomized, double-blind, placebo-controlled trial [34] showed that 4,000 mg milk protein concentrate per day (Microlactin™; Stolle Milk Biologics Inc., Cincinnati, OH, USA) yields significant improvement in WOMAC score after 2 weeks of treatment on OA patients.

In OA patients, MMPs such as MMP-3 are over-expressed and abundant in fluids of the synovial cavity, and cause degeneration of cartilage tissue [35, 36]. 5-Loxin® was able to reduce the elevated MMP-3 level in synovial fluid. This finding indicates that reduction in synovial fluid MMP-3 level by 5-Loxin® is consistent with improvements in abnormal joint physiology in OA. Therefore, these data together demonstrate that 5-Loxin® potentially has effects in terms of reducing the pain and improving physical ability and joint health; it is most likely that these improvements occur through downregulation of cartilage degrading enzymes such as MMP-3.

Earlier, in acute and subchronic toxicity studies we demonstrated that 5-Loxin® (a 30% enriched product of AKBA, which is the active component of Boswellia extract) is safe and nontoxic in rats [15]. Additionally, 5-Loxin® did not exhibit mutagenicity in the standard AMES test (INTOX; study no. 4477/05). In the present study biochemical parameters in serum, haematological parameters and urine analysis (Table 3) also did not reveal any major adverse effect of the test compound in OA patients. Taken together, these observations further demonstrate that 5-Loxin® is potentially safe in the treatment of OA in humans.

Conclusion

In summary, the present study provides the evidence in support of the potential efficacy and safety of 5-Loxin® in patients with OA: 5-Loxin® significantly improved joint function and exhibited better therapeutic efficacy at 250 mg/day than at 100 mg/day; it reduces pain rapidly, as early as after 1 week of treatment; it reduces levels of the cartilage degrading enzyme MMP-3 in synovial fluid; and, most importantly, 5-Loxin® is safe for human consumption, even long term. This study provides important information about the efficacy and safety of 5-Loxin® in the treatment of OA, which may be useful in promoting 5-Loxin® as a promising alternative therapeutic strategy that may be used as a nutritional supplement against OA.

Abbreviations

AKBA: 

= 3-O-acetyl-11-keto-beta-boswellic acid

ANOVA: 

= analysis of variance

ASRAM: 

= Alluri Sitarama Raju Academy of Medical Sciences

BMI: 

= Body Mass Index

ELISA: 

= enzyme-linked immunosorbent assay

LFI: 

= Lequesne's Functional Index

MMP: 

= matrix metalloproteinase

NSAID: 

= nonsteroidal anti-inflammatory drug

NU: 

= normalized units

OA: 

= osteoarthritis

VAS: 

= visual analog scale

WOMAC: 

= Western Ontario and McMaster Universities Osteoarthritis Index.

Declarations

Acknowledgements

This study is funded by Laila Impex R&D Center, India.

Authors’ Affiliations

(1)
Cellular and Molecular Biology Division, Laila Impex R&D Center, Vijayawada, India
(2)
Pharmacology Division, Laila Impex R&D Center, Vijayawada, India
(3)
Department of Orthopedics, Alluri Sitarama Raju Academy of Medical Sciences (ASRAM), Eluru, India
(4)
Department of Internal Medicine, Alluri Sitarama Raju Academy of Medical Sciences (ASRAM), Eluru, India
(5)
Drug Discovery and Development Division, Laila Impex R&D Center, Vijayawada, India
(6)
Department of Statistics, SV University, Tirupati, India
(7)
Department of Statistics, University of Connecticut, Storrs, Connecticut, USA
(8)
Department of Medicine, Division of Rheumatology, Allergy and Immunology, School of Medicine, U C Davis and VA Medical Center Sacramento, Mather, California, USA

References

  1. Felson DT: An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 2004, 42: 1-9. 10.1016/S0033-8389(03)00161-1.View ArticlePubMedGoogle Scholar
  2. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000, 133: 635-646.View ArticlePubMedGoogle Scholar
  3. Green GA: Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001, 3: 50-60. 10.1016/S1098-3597(01)90069-9.View ArticlePubMedGoogle Scholar
  4. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995, 38: 1541-1546. 10.1002/art.1780381104.View ArticlePubMedGoogle Scholar
  5. Anonymous: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000, 43: 1905-1915. 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P.View ArticleGoogle Scholar
  6. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, Cluzeau F, Cooper C, Dieppe PA, Günther KP, Hauselmann HJ, Herrero-Beaumont G, Kaklamanis PM, Leeb B, Lequesne M, Lohmander S, Mazieres B, Mola EM, Pavelka K, Serni U, Swoboda B, Verbruggen AA, Weseloh G, Zimmermann-Gorska I: EULAR recommendations for the management of osteoarthritis: report of task force standing committee for International Clinical Studies including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000, 59: 936-944. 10.1136/ard.59.12.936.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Singh G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998, 105:Google Scholar
  8. Griffin MR: Epidemiology of nonsteroidal anti-inflammatory drug associated gastrointestinal injury. Am J Med. 1998, 104:Google Scholar
  9. Wright JM: Double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002, 167: 1131-1137.PubMed CentralPubMedGoogle Scholar
  10. Singh GB, Atal CK: Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions. 1986, 18: 407-412. 10.1007/BF01965005.View ArticlePubMedGoogle Scholar
  11. Ethan B, Heather B, Theresa DH, Ivo F, Sadaf H, Jens H, David S, Catherine U: Boswellia: An evidence-based systematic review by the natural standard research collaboration. J Herbal Pharmacother. 2004, 4: 63-83. 10.1300/J157v04n02_07.Google Scholar
  12. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HPT: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992, 26: 1143-1146.Google Scholar
  13. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HPT, Safayhi H: Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements or binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996, 117: 615-618.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss H, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Bagchi D, Sen CK: Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol. 2005, 24: 244-255. 10.1089/dna.2005.24.244.View ArticlePubMedGoogle Scholar
  15. Lalithakumari K, Krishnaraju AV, Sengupta K, Subbaraju GV, Chatterjee A: Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-β-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin). Toxicol Mechanisms Methods. 2006, 16: 199-226. 10.1080/15376520600620232.View ArticleGoogle Scholar
  16. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B: Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006, 6: 19-10.1186/1472-6882-6-19.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF: Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G1131-G1137. 10.1152/ajpgi.00562.2005.View ArticlePubMedGoogle Scholar
  18. Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP: Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001, 67: 391-395. 10.1055/s-2001-15802.View ArticlePubMedGoogle Scholar
  19. Kimmatkar N, Thawani V, Hingorani L, Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003, 10: 3-7. 10.1078/094471103321648593.View ArticlePubMedGoogle Scholar
  20. Bellamy N, Buchnan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988, 15: 1833-1840.PubMedGoogle Scholar
  21. Lequesne MG, Mery C, Samson M, Gerard P: Indexes of severity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. Scand J Rheumatology. 1987, 65: 85-89. 10.3109/03009748709102182.View ArticleGoogle Scholar
  22. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE: Pain measurement: an overview. Pain. 1985, 22: 1-31. 10.1016/0304-3959(85)90145-9.View ArticlePubMedGoogle Scholar
  23. Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R: The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI. Osteoarthritis Cartilage. 2005, 13: 104-110. 10.1016/j.joca.2004.10.016.View ArticlePubMedGoogle Scholar
  24. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000, 160: 1781-1787. 10.1001/archinte.160.12.1781.View ArticlePubMedGoogle Scholar
  25. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ: Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002, 41: 1052-1061. 10.1093/rheumatology/41.9.1052.View ArticleGoogle Scholar
  26. Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM: Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2007, 46: 496-507. 10.1093/rheumatology/kel296.View ArticleGoogle Scholar
  27. Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS: Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis. 2007, 66: 945-951. 10.1136/ard.2006.059162.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Power analysis for ANOVA designs. [http://www.math.yorku.cal/SCS/Online/power/]
  29. Garnero P, Rousseau J, Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in joint diseases. Arthritis Rheum. 2000, 43: 953-968. 10.1002/1529-0131(200005)43:5<953::AID-ANR1>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
  30. Felson DT: Osteoarthritis of the knee. N Engl J Med. 2006, 354: 841-848. 10.1056/NEJMcp051726.View ArticlePubMedGoogle Scholar
  31. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE: The importance of placebo effects in pain treatment and research. JAMA. 1994, 271: 1609-1614. 10.1001/jama.271.20.1609.View ArticlePubMedGoogle Scholar
  32. Walach H, Sadaghiani C, Dehm C, Bierman D: The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials: a secondary analysis. BMC Med Res Methodol. 2005, 5: 26-37. 10.1186/1471-2288-5-26.PubMed CentralView ArticlePubMedGoogle Scholar
  33. McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000, 283: 1469-1475. 10.1001/jama.283.11.1469.View ArticlePubMedGoogle Scholar
  34. Zenk JL, Helmer TR, Kuskowski MA: The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomized, double blind, placebo-controlled trial. Curr Ther Res. 2002, 63: 430-442. 10.1016/S0011-393X(02)80049-2.View ArticleGoogle Scholar
  35. Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000, 19: 333-344. 10.1016/S0945-053X(00)00078-0.View ArticlePubMedGoogle Scholar
  36. Little CB, Hughes CE, Curtis CL, Janusz MJ, Bohne R, Wang-Weigand S, Taiwo YO, Mitchell PG, Otterness IG, Flannery CR, Caterson B: Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 2002, 21: 271-288. 10.1016/S0945-053X(02)00004-5.View ArticlePubMedGoogle Scholar

Copyright

© Sengupta et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us